Ionis reports fourth quarter and full year 2023 financial results

WAINUA™ approved with launch underway; on track for EU and Canada approval decisions this year
Positive Phase 3 olezarsen and donidalorsen data, preparing regulatory submissions for FCS and HAE,...

Related Keywords

Canada ,Elizabethl Hougen , ,Astrazeneca ,Novartis ,Linkedin ,Company Phase ,Nasdaq ,Ionis Pharmaceuticals ,Foundation For Angelman Syndrome Therapeutics Summit ,Akcea Therapeutics Inc ,Ionis Pharmaceuticals Inc ,Exchange Commission ,Technology Advancement ,Breakthough Therapy ,Full Year ,Fast Track ,Breakthrough Therapy ,Angelman Syndrome Therapeutics ,Royalty Pharma ,Serum Vitamin ,Recommended Supplementation ,Prescribing Information ,Akcea Therapeutics ,Consolidated Statements ,Except Per Share Data ,Consolidated Operating Expenses ,From Operations ,Net Income ,Selected Financial Information ,Data Events ,Markets ,